Artemis Medicare Services Limited has announced a board meeting scheduled for February 2, 2026, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will address key financial and strategic matters for the healthcare services company.

Board Meeting Agenda

The board meeting will focus on two primary objectives during the February 2, 2026 session:

Fund Raising Proposals Under Consideration

The board will evaluate comprehensive fund raising proposals involving multiple financial instruments and methods. The company is considering issuance of various securities including:

• Equity shares
• Fully or partly convertible debentures
• Non-convertible debentures along with warrants
• Other equity-based securities
• Any combination of the above instruments

The fund raising may be executed through several methods including preferential allotment, private placement, Qualified Institutions Placements (QIP), or any combination thereof. The proposals will be structured in one or more tranches as deemed appropriate by the board.

Regulatory Compliance and Approvals

The fund raising initiatives will require compliance with applicable provisions of the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company has indicated that necessary approvals will be sought, including member approval and other regulatory and statutory approvals as required.

Trading Window Restrictions

Artemis Medicare Services has implemented trading window restrictions in accordance with regulatory requirements:

The trading window for dealing in company securities remains closed and will continue until 48 hours after the declaration of unaudited financial results. This restriction was previously communicated to stakeholders on December 29, 2025.

Corporate Communication

The formal intimation was signed by Poonam Makkhar, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited on January 28, 2026. The company trades under NSE symbol ARTEMISMED and BSE scrip code 542919.

Artemis Medicare Services Limited has completed the allotment of equity shares under its employee stock option scheme, marking another step in its capital structure evolution. The healthcare company announced the allotment of shares to grantees who exercised their vested options under the established stock option plan.

Share Allotment Details

The company has allotted 1,05,750 equity shares under its Management Stock Option Plan-2021. These shares have been issued as fully paid-up equity shares with a face value of ₹1 each.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The capital structure change reflects the exercise of vested options by eligible grantees under the stock option plan.

Share Characteristics

The newly allotted equity shares carry identical rights and privileges as existing equity shares of the company. They will rank pari-passu with the existing equity shares of the company.

Regulatory Compliance

The company has fulfilled its disclosure obligations regarding the allotment of shares under its employee stock option scheme. This action aligns with Artemis Medicare Services' commitment to employee participation in equity ownership while maintaining compliance with regulatory frameworks governing employee stock option schemes in the healthcare sector.